Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Long-Term Debt Repayments (2022 - 2025)

SAB Biotherapeutics (SABS) has disclosed Long-Term Debt Repayments for 4 consecutive years, with $3.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Debt Repayments fell 100.0% year-over-year to $3.0, compared with a TTM value of $275849.0 through Dec 2025, down 78.63%, and an annual FY2025 reading of $275849.0, down 78.63% over the prior year.
  • Long-Term Debt Repayments was $3.0 for Q3 2025 at SAB Biotherapeutics, down from $138551.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $761050.0 in Q2 2022 and bottomed at $3.0 in Q3 2025.
  • Average Long-Term Debt Repayments over 4 years is $323711.2, with a median of $254913.0 recorded in 2022.
  • The sharpest move saw Long-Term Debt Repayments soared 450.36% in 2024, then tumbled 100.0% in 2025.
  • Year by year, Long-Term Debt Repayments stood at $488437.0 in 2022, then crashed by 47.59% to $255989.0 in 2023, then dropped by 6.19% to $240133.0 in 2024, then crashed by 100.0% to $3.0 in 2025.
  • Business Quant data shows Long-Term Debt Repayments for SABS at $3.0 in Q3 2025, $138551.0 in Q2 2025, and $137295.0 in Q1 2025.